Citations

Clear

20 citation(s) found for "Rao, Sunil V".

Temporal Trends and Predictors of Access Site Crossover During PCI in Contemporary Practice: A Report From the NCDR CathPCI Registry
Reynolds, E O R , Marks, Angel , Wojdyla, Daniel, Smilowitz, Nathaniel R. , Gilchrist, Ian C. , Gulati, Rajiv , Rao, Sunil V. , Reynolds, Eli , Shah, Binita , Marks, Angel , Wojdyla, Daniel , Smilowitz, Nathaniel R , Rymer, Jennifer A , Gilchrist, Ian C , Gulati, Rajiv , Rao, Sunil V , Shah, Binita

Mayo Clinic

Circulation: Cardiovascular Interventions | July 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circinterventions.126.016673 | PMID 42473791 Get It

BACKGROUND: Randomized trials comparing radial and femoral access report access site crossover rates of 3% to 9% for radial access and 1% to 3% for femoral access. However, contemporary real-world crossover rates are not well characterized. The aim was to evaluate contemporary trends and predictors of vascular access site crossover during percutaneous coronary intervention (PCI). METHODS: We analyzed index PCI procedures recorded in the National Cardiovascular Data Registry CathPCI Registry from 2018 to 2024. Access site crossover was identified using documented access data, with radial-to-femoral crossover inferred when the final successful access site was femoral. Temporal trends and clinical predictors of crossover were examined. Operator experience was assessed using cumulative total and radial PCI volumes from 2011 to 2024 as captured in CathPCI Registry versions 4 and 5. RESULTS: Among 3 861 790 index PCIs, 192 902 (5.0%) involved access site crossover, with a modest increase over time. Radial-to-femoral crossover accounted for 81.2% of crossover events. Factors independently associated with crossover included older age, female sex, higher body mass index, and peripheral vascular disease. Operators with the lowest total PCI volume and the lowest radial PCI volume experienced the highest crossover rates. Notably, operators with low radial PCI volume demonstrated a substantial decline in radial-to-femoral crossover over the study period. CONCLUSIONS: In contemporary clinical practice, access site crossover rates are consistent with those reported in randomized trials. Although crossover occurs more frequently among lower-volume operators, rates decline with increasing operator experience, supporting the presence of a radial access learning curve and improvement in procedural performance over time.
Donor-derived Cell-free DNA for Detection of Rejection After Pancreas Transplantation
Matar, Abraham J. , Sarumi, Heidi, Finger, Erik, Humphreville, Vanessa , Ramanathan, Karthik, Fisher, J. Elwood, Rao, J. Sunil , Prewett, Adam , Tabriziani, Hossein , Kandaswamy, Raja, Megaly, Michael S. , Riad, Samy , Sarumi, Heidi , Megaly, Michael , Wright, Matthew, Finger, Erik, Ramanathan, Karthik V. , Fisher, Jessica, Demko, Zachary P , Kandaswamy, Raja

Mayo Clinic

Transplantation Direct | April 8, 2026 | Volume: 12 | Issue: 5 | Pages: e1939

10.1097/txd.0000000000001939 | PMID 41972229 Get It

Background. Donor-derived cell-free DNA (dd-cfDNA) has emerged as a promising noninvasive biomarker for detecting allograft rejection in solid organ transplantation. However, its diagnostic utility in pancreas transplantation, including in multiorgan recipients, remains underexplored. Methods. We conducted a retrospective analysis of 42 pancreas transplant recipients (38 simultaneous pancreas-kidney, 4 pancreas transplant alone) who underwent for-cause organ biopsy and dd-cfDNA testing between April 2020 and December 2024. dd-cfDNA was measured using the Prospera assay, with a threshold of ≥1% considered high risk and <1% low-risk. Biopsy results were correlated with dd-cfDNA to assess test performance. Results. A total of 50 dd-cfDNA tests and 45 organ biopsies were analyzed. Among simultaneous pancreas-kidney recipients, dd-cfDNA demonstrated a sensitivity of 86.7%, specificity of 52.2%, positive predictive value (PPV) of 54.2%, and negative predictive value (NPV) of 85.7% for rejection. In pancreas transplant alone recipients, all high-risk dd-cfDNA results corresponded to biopsy-proven rejection, yielding 100% sensitivity, specificity, PPV, and NPV. When combining both cohorts, dd-cfDNA testing achieved an overall sensitivity of 88.2%, specificity of 57.7%, PPV of 57.7%, and NPV of 88.2%. Additionally, dd-cfDNA kinetics suggested its potential utility as a surveillance tool posttreatment, potentially reducing the need for closure biopsies. Conclusions. dd-cfDNA is a valuable noninvasive adjunct for monitoring of rejection in pancreas transplant recipients. Further prospective studies are needed to validate these findings and define the optimal role of dd-cfDNA in posttransplant care.
Validation of the Mayo Clinic Percutaneous Coronary Intervention Risk Prediction Score in Patients With Acute Coronary Syndrome
Landi, Antonio , Zito, Andrea , Singh, Mandeep , Angiolillo, Dominick J. , Frigoli, Enrico , Rao, Sunil V. , Urban, Philip , Valgimigli, Marco , Capodanno, Davide , Rao, Sunil V , Valgimigli, Marco , Angiolillo, Dominick J , Milzi, Andrea

Mayo Clinic

Journal of the American Heart Association | October 9, 2025 | Volume: 14 | Issue: 20 | Pages: No page available

10.1161/jaha.125.043012 | PMID 41065238 Get It

Background A contemporary, comprehensive risk score for the prediction of in‐hospital fatal and nonfatal adverse events after percutaneous coronary intervention has been recently developed, albeit its external validation in patients with acute coronary syndrome is lacking. The objective of this study is to validate the Mayo Clinic integer risk score in a large cohort of patients with acute coronary syndrome undergoing percutaneous coronary intervention from the MATRIX (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox) trial. Methods The risk score is composed of a common set of 23 clinical and procedural variables (model A) and 18 preprocedural variables (model B). The primary objective was to appraise the receiver‐operator characteristics of both models for in‐hospital mortality, bleeding, contrast‐associated acute kidney injury, and stroke. The impact of risk score categories on 1‐year outcomes was also investigated. Results Among the 6724 patients undergoing percutaneous coronary intervention in the MATRIX trial, the receiver‐operator characteristics—area under the curves for in‐hospital mortality, bleeding, contrast‐associated acute kidney injury, and stroke were 0.88 (95% CI, 0.85–0.91), 0.66 (95% CI, 0.63–0.69), 0.70 (95% CI, 0.67–0.72), and 0.65 (95% CI, 0.52–0.78) for model A and 0.88 (95% CI, 0.84–0.92), 0.63 (95% CI, 0.60–0.66), 0.66 (95% CI, 0.63–0.69), and 0.65 (95% CI, 0.52–0.78) for model B, respectively. Mortality (model A), bleeding, and stroke risks were well calibrated, whereas mortality (model B) and contrast‐associated acute kidney injury risk were underestimated. There was a gradual risk increase for 1‐year mortality and bleeding as a function of the risk score tertile using both models. Conclusions The risk score identifies patients with acute coronary syndrome at incremental risk of in‐hospital mortality, bleeding, contrast‐associated acute kidney injury, and stroke, representing a valuable tool for mitigation of modifiable risk factors. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT01433627.
Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis
Ullah, Waqas , Sandhyavenu, Harigopal , Taha, Amro , Gowda, Smitha Narayana , Mukhtar, Maryam , Polam, Aravind Reddy , Zahid, Salman , Fischman, David L. , Savage, Michael P. , Rao, Sunil V. , Reddy Polam, Aravind , Alkhouli, Mohamad , Mukhtar, Maryam , Rao, Sunil V , Fischman, David , Sandhyavenu, Harigopal , Alkhouli, Mohamad

Mayo Clinic

Journal of the American Heart Association | October 11, 2024 | Volume: 13 | Issue: 20 | Pages: No page available

10.1161/jaha.122.032490 | PMID 39392170 Get It

Background Optimal duration and choice of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention remain controversial. Methods and Results Digital databases (PubMed, Cochrane, and Embase) were queried to select all randomized controlled trials on a post–percutaneous coronary intervention population with acute coronary syndrome. Dual‐antiplatelet therapy (DAPT) with aspirin and clopidogrel for 12 months was compared with 4 major strategies: high‐potency, high‐ to low‐potency, low‐dose, and short‐duration DAPT. A network meta‐analysis was performed to compare the safety and efficacy of different antiplatelet strategies. This study was the second updated manuscript under the International Prospective Register of Systematic Review registration (CRD42021286552). Thirty‐two randomized controlled trials comprising 103 459 (51 750 experimental, 51 709 control) patients were included. Compared with DAPT with aspirin and clopidogrel for 12 months, high‐ to low‐potency DAPT (risk ratio [RR], 0.69 [95% CI, 0.52–0.92]) and aspirin+prasugrel containing DAPT for 12 months (RR, 0.84 [95% CI, 0.72–0.98]) had a significantly lower, whereas DAPT for 1 month followed by clopidogrel only (RR, 1.59 [95% CI, 1.06–2.39]) had a higher, incidence of major adverse cardiovascular events at 1 year (median follow‐up). Prasugrel (RR, 1.35 [95% CI, 1.09–1.66]) and ticagrelor (RR, 1.38 [95% CI, 1.17–1.62]) containing DAPT for 12 months had significantly higher rates, whereas high‐ to low‐potency DAPT (RR, 0.85 [95% CI, 0.63–1.15]) had no significant risk of major bleeding. Conclusions Aspirin and ticagrelor for 3 months, followed by aspirin and clopidogrel for the remaining duration, can be considered the optimal strategy for treating post–percutaneous coronary intervention patients with acute coronary syndrome because of a significantly reduced risk of major adverse cardiovascular events without increasing the risk of bleeding.
Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium
Mehran, Roxana , Krucoff, Mitchell W., Baber, Usman , Bhatt, Deepak L. , Collet, Jean‐Philippe, Cuisset, Thomas, Luca, Leonardo De , Farb, Andrew , Hong, Myeong‐Ki , Kimura, Takeshi , Magee, Adrian, Matsumura, Ryosuke, Mochizuki, Shuichi , Pereira, Naveen L. , Rollini, Fabiana , Shirai, Yuko, Sibbing, Dirk , Smits, Peter C., Storey, Robert F. , Windecker, Stephan , Yeh, Robert W. , Morice, Marie‐Claude, Capodanno, Davide , Mehran, Roxana , Bhatt, Deepak L , De Luca, Giuseppe , De Luca, Leonardo , Hahn, Joo‐Yong , Hong, Myeong-Ki , James, Stefan Karl , Kastrati, Adnan , Kimura, Takeshi , Lemos, Pedro A , Lopes, Renato D , Mochizuki, Shuichi , O'Donoghue, Michelle L , Pereira, Naveen L , Rao, Sunil V , Smits, Peter C , Steg, P Gabriel , Storey, Robert F , Ten Berg, Jurrien , Valgimigli, Marco , Vranckx, Pascal , Watanabe, Hirotoshi , Windecker, Stephan , Serruys, Patrick W , Yeh, Robert W , Angiolillo, Dominick J , Capranzano, Piera , Collet, Jean‐Philippe , Cuisset, Thomas , Franchi, Francesco , Gibson, C. Michael , Lópes, Renato D. , Matsumura, Ryosuke, Rao, Sunil V. , Shirai, Yuko, Sibbing, Dirk , Steg, Philippe Gabríel , Valgimigli, Marco , Serruys, Patrick W. , Angiolillo, Dominick J.

Mayo Clinic

Circulation | June 19, 2023 | Volume: 147 | Issue: 25 | Pages: 1933-1944

10.1161/circulationaha.123.064473 | PMID 37335828 Get It

Antiplatelet therapy is the mainstay of pharmacologic treatment to prevent thrombotic or ischemic events in patients with coronary artery disease treated with percutaneous coronary intervention and those treated medically for an acute coronary syndrome. The use of antiplatelet therapy comes at the expense of an increased risk of bleeding complications. Defining the optimal intensity of platelet inhibition according to the clinical presentation of atherosclerotic cardiovascular disease and individual patient factors is a clinical challenge. Modulation of antiplatelet therapy is a medical action that is frequently performed to balance the risk of thrombotic or ischemic events and the risk of bleeding. This aim may be achieved by reducing (ie, de-escalation) or increasing (ie, escalation) the intensity of platelet inhibition by changing the type, dose, or number of antiplatelet drugs. Because de-escalation or escalation can be achieved in different ways, with a number of emerging approaches, confusion arises with terminologies that are often used interchangeably. To address this issue, this Academic Research Consortium collaboration provides an overview and definitions of different strategies of antiplatelet therapy modulation for patients with coronary artery disease, including but not limited to those undergoing percutaneous coronary intervention, and consensus statements on standardized definitions.
Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank
Naidu, Srihari S. , Baron, Suzanne J. , Eng, Marvin H. , Sathanandam, Shyam , Zidar, David A., Feldman, Dmitriy N. , Ing, Frank F. , Latif, Faisal , Lim, Michael J. , Henry, Timothy D. , Dangas, George , Hermiller, James, Daggubati, Ramesh , Ang, Lawrence , Box, Lyndon C., Caputo, Ronald , Cohen, Mauricio G. , Coylewright, Megan , Duffy, Peter L. , Goldsweig, Andrew M. , Hagler, Donald J. , Hawkins, Beau M., Hijazi, Ziyad M. , Jayasuriya, Sasanka, Klein, Andrew , Kliger, Chad , Mahmud, Ehtisham , Messenger, John C. , Parikh, Sahil A. , Shishehbor, Mehdi H. , Yakubov, Steven J. , Alvarez‐Breckenridge, Jennifer, Baird, Colleen, Baker, David, Berry, Charles H., Bhattacharya, Manisha, Bilazarian, Seth, Bowen, Rosanne, Brounstein, Kevin, Cameron, Cole, Culbertson, Casey , Díaz, P, Emanuele, Susan, Evans, Erin, Fletcher, Rob, Fortune, Tina, Gaiha, Priya, Govender, Devi, Gutfinger, Dan , Haggstrom, Kurt, Herzog, Andrea, Hite, Denise, Kalich, Bethany , Kirkland, Ann, Kohler, Toni, Laurisden, Holly, Livolsi, Kevin, Lombardi, Lois, Marhenke, Kevin, Meikle, Joie, Moat, Neil, Popma, J.J., Rangwala, Novena , Simonton, Chuck, Stokes, J. W., Taber, Margaret , Tieché, Christopher, Venditto, John, Zinn, Laurie, Dangas, George , Daggubati, Ramesh , Shah, Binita , Ang, Lawrence , Cohen, Mauricio G , Goldsweig, Andrew M , Hagler, Donald J , Morray, Brian H , Parikh, Sahil A , Shishehbor, Mehdi H , Szerlip, Molly , Yakubov, Steven J , Grines, Cindy L , Baron, Suzanne J , Rao, Sunil V. , Shah, Binita , Aronow, Herbert D. , Banerjee, Subhash , Justino, Henri , Li, Jun , Morray, Brian H. , Parikh, Sahil A. , Reilly, John P. , Secemsky, Eric A. , Grines, Cindy L. , Baker, David, Berry, Charles, Cavalcante, Rafael , Diaz, Pedro, Kohler, Toni, Lowe, Sarah, Mueller, Megan, Patarca, Roberto , Stokes, Jerry, West, Nick E.J.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 16, 2021 | Volume: 98 | Issue: 5 | Pages: 904-913

10.1002/ccd.29898 | PMID 34398509 Get It

AbstractThe Society for Cardiovascular Angiography and Interventions (SCAI) Think Tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community annually for high‐level field‐wide discussions. The 2021 Think Tank was organized into four parallel sessions reflective of the field of interventional cardiology: (a) coronary intervention, (b) endovascular medicine, (c) structural heart disease, and (d) congenital heart disease. Each session was moderated by a senior content expert and co‐moderated by a member of SCAI's Emerging Leader Mentorship program. This document presents the proceedings to the wider cardiovascular community in order to enhance participation in this discussion, create additional dialog from a broader base, and thereby aid SCAI, the industry community and external stakeholders in developing specific action items to move these areas forward.
A nationwide analysis of 16 year trends in cardiac transplantation for cardiac sarcoidosis
Perembeti, S, Correa, Ashish , Padmanabhan, Deepak , Garg, Vinisha , Contreras, J, Isath, Ameesh , Chahal, C. Anwar A. , Rao, Sunil V.

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.1113 Get It

Abstract Background Orthotopic heart transplant (OHT) is indicated for end-stage heart failure due to cardiac sarcoidosis (CS). However, utilization of OHT for CS has been controversial due to concern for involvement of other organs by sarcoidosis affecting long term outcomes. Purpose Our objective was to study the trends in OHT in patients with CS in the United States using Healthcare Cost and Utilization Project (HCUP) National (nationwide) Inpatient Sample (NIS) from 1999 to 2014. Methods Using NIS data, we identified patients older than 18 years with cardiac sarcoidosis using codes ICD 9-CM codes of 135 and 425.8. Among these patients, we identified those who underwent cardiac transplantation using ICD 9-CM procedure codes 37.5 and 33.6. We presented categorical data as percentages and continuous data as mean or median as appropriate. Results A weighted total of 24231 hospitalizations for CS was extracted from 1999 to 2014 of which 248 (1.02%) CS patients underwent OHT. The trends in cardiac transplant for CS is as shown in Figure 1. The mean age of CS patients undergoing OHT was 51.7±1.1 years and 60.4% (n=150) were males. 114 (45.9%) were Caucasians and 27.8% (n=25) were African-American. 100% of the transplants were performed at medium (n=5) or large sized (n=243) teaching hospitals and 97.9% of cardiac transplants were also done at teaching hospitals. Heart transplants were mostly done in the South (36.3%) followed by Midwest (26.2%), West (25%) and Northeast (12.5%). Private insurance was the major payor source which covered 149 (60.1%) patients followed by Medicare covering 65 (26.2%) patients. A total of 10 (3.9%) cardiac sarcoidosis patients died during the same hospitalization for cardiac transplantation. Following OHT, 84.2% (n=209) were discharged home and 11.6% (n=29) to short term hospitalization. The mean cost of hospitalization for OHT in CS when adjusted for inflation was 535144±56060 dollars while the average length of stay for heart transplant for CS was 46.2±6.6 days. Conclusions Cardiac transplant trends in CS have not changed from 1999 to 2014 despite recent studies showing improved outcomes and are associated with substantial cost of hospitalization and length of stay. Majority of cardiac transplant was done in Caucasians despite cardiac sarcoidosis being more common in African-Americans. Funding Acknowledgement Type of funding source: None
A nationwide 16 year analysis of trends and impact of arrythmias in transplant recipients
Perembeti, S, Sherif, Aida, Correa, Ashish , Padmanabhan, Deepak , Garg, Vinisha , Contreras, J, Mehta, Davendra, Isath, Ameesh , Rao, Sunil Kumar , Sherif, A, Chahal, C. Anwar A.

Mayo Clinic

European Heart Journal | November 26, 2020 | Volume: 41 | Issue: Supplement_2 | Pages: No page available

10.1093/ehjci/ehaa946.0347 Get It

Abstract Background Orthotopic heart transplantation is the most effective long-term therapy for end-stage heart disease. Denervation of transplanted heart with the loss of autonomic modulation, vasculopathy, utilization of immunosuppressant drugs, and risk of allograft rejection may result in change in the prevalence of arrhythmias in transplanted hearts. Purpose To describe the trends, distribution and the clinical impact of arrhythmias in transplanted hearts in a large nationwide population. Methods We queried the National Inpatient Sample with administrative codes. Cardiac transplant patients were identified using procedure ICD-9-CM codes 37.5 and 33.6. Common arrhythmias were extracted using appropriate validated ICD-9-CM codes. Statistical Analysis System (SAS) version 9.4 was used for analysis of data. Results There was a total of 30,020 hospitalizations of heart transplant recipients between 1999 and 2014 in the United States and 16342 (54.4%) of these had arrhythmias. The prevalence of total arrhythmias increased from 53.6% (n=1,158) in 1999 to 67.3% (n=1,575) in 2014. The most common arrhythmia was atrial fibrillation (26.83%) followed by ventricular tachycardia (22.86%) and the prevalence of individual arrhythmias is as shown in Figure 1. Cardiogenic shock was higher in transplanted hearts with arrhythmias when compared with patients without arrhythmias (25.96% vs 18.18%; p&lt;0.001). Transplant recipients with arrhythmias were also associated with an increased use of mechanical circulatory device (18.22% vs 12.67%, p&lt;0.001). The use of implantable cardiac defibrillators and permanent pacemaker was also higher in the arrhythmia group (2.19% vs 0.63% and 40.43% vs 30.24% respectively, p&lt;0.0001). However, there was no significant difference in inpatient mortality between transplant recipients with arrhythmias and without arrhythmias (7.72% vs 6.90%, p=0.225). Further, there was no significant difference in frequency of strokes between the groups (4.98% vs 5.08%; p=0.857). The total hospital cost when adjusted for inflation was significantly higher in the arrhythmic patients, with an average cost of about $570,415±9,590 vs $439,707±8362 in patients without arrhythmias (p&lt;0.0001). The mean length of hospitalization was 44.2±0.8 days in patients with arrhythmias compared to 33.9±0.8 days in patients without arrhythmias (p&lt;0.0001). Conclusion A significant proportion of patients with heart transplant have cardiac arrhythmias and are associated with worse in-hospital outcomes of cardiogenic shock, increased length of stay, and cost of hospitalization. However, they are not associated with worse inpatient mortality. Funding Acknowledgement Type of funding source: None
Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice
Sherwood, Matthew W. , Piccini, Jonathan P. , Holmes, DaJuanicia N. , Pieper, Karen S. , Kowey, Peter R. , Mahaffey, Kenneth W. , Singer, Daniel E. , Ansell, Jack , Reiffel, James A. , Blanco, Rosalia , Steinberg, Benjamin A. , Fonarow, Gregg C. , Allen, Larry A. , Naccarelli, Gerald V. , Gersh, Bernard J. , Freeman, James V. , Chan, Paul S. , Peterson, Eric D. , Rao, Sunil V.

Mayo Clinic

Circulation: Cardiovascular Interventions | May 15, 2020 | Volume: 13 | Issue: 5 | Pages: No page available

10.1161/circinterventions.119.008274 | PMID 32408815 Get It

Background: Patients with atrial fibrillation on oral anticoagulation (OAC) undergoing cardiac catheterization face risks for embolic and bleeding events, yet information on strategies to mitigate these risks in contemporary practice is lacking. Methods: We aimed to describe the clinical/procedural characteristics of a contemporary cohort of patients with atrial fibrillation on OAC who underwent cardiac catheterization. Use of bleeding avoidance strategies and bridging therapy were described and outcomes including death, stroke, and major bleeding at 30 days and 1 year were compared by OAC type. Results: Of 13 404 patients in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II Registry from 2013 to 2016, 741 underwent cardiac catheterization (139 with percutaneous coronary intervention) in the setting of OAC. The patients’ median age was 71, 61.8% were male, white (87.2%), had hypertension (83.7%), hyperlipidemia (72.1%), diabetes mellitus (31.6%), and chronic kidney disease (28.2%); 20.2% received warfarin while 79.8% received direct acting oral anticoagulant. One third of patients underwent radial artery access, and bivalirudin was used in 4.6%. Bridging therapy was used more often in patients on warfarin versus direct acting oral anticoagulant (16.7% versus10.0%). OAC was interrupted in 93.8% of patients. Patients on warfarin versus direct acting oral anticoagulant were equally likely to restart OAC (58.0% versus 60.7%), had similar use of antiplatelet therapy (44.0% versus 41.3%) after catheterization, and had similar rates of myocardial infarction and death at 1 year, but higher rates of major bleeding (43.3 versus 12.9 events/100 patient years) and stroke (4.9 versus 1.9 events/100 patient years). Conclusions: In a real-world registry of patients with atrial fibrillation undergoing cardiac catheterization, most cases are elective, performed by femoral access, with interruption of OAC. Bleeding avoidance strategies such as radial artery access and bivalirudin were used infrequently and use of bridging therapy was uncommon. Nearly 40% of patients did not restart OAC postprocedure, exposing patients to risk for stroke. Further research is necessary to optimize the management of patients with atrial fibrillation undergoing cardiac catheterization.
Response by Latif et al to Letter Regarding Article, "Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial"
Latif, Faisal , Uyeda, Lauren , Edson, Robert , Bhatt, Deepak L. , Goldman, Steven , Holmes, David R. , Shunk, Kendrick , Aggarwal, Kul, Bolad, Islam, McFalls, Edwards, Irimpen, Anand, Truong, Huu Tam, Kinlay, Scott , Velagaleti, Raghava S. , Rangan, Bavana V. , Mavromatis, Kreton , Shih, Mei-Chiung , Bhatt, Deepak L , Rao, Sunil V. , Uretsky, Barry F. , Ziada, Khaled M. , Papademetriou, Vasilios , Banerjee, Subhash , Brilakis, Emmanouil S.

Mayo Clinic

Circulation: Cardiovascular Interventions | April 13, 2020 | Volume: 13 | Issue: 4 | Pages: No page available

10.1161/circinterventions.120.009174 | PMID 32279564 Get It